![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » NICE Endorses Novartis’ Cosentyx in PsA
NICE Endorses Novartis’ Cosentyx in PsA
The National Institute for Health and Care Excellence (NICE) has released a positive final appraisal determination for Novartis’ Cosentyx (secukinumab) for use in adults with active and progressive psoriatic arthritis.
NICE is recommending use of Cosentyx when a patient has peripheral arthritis with three or more tender joints and three or more swollen joints and has not responded to adequate trials of at least two standard disease-modifying antirheumatic drugs, administered either individually or in combination.
The drug is a biologic therapy that selectively binds to IL17A and stops it from binding to its receptors and prevents inflammation.
Upcoming Events
-
21Oct